Please assess the completion status of the following clinical trial:

Trial Title: Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* IBS confirmed by Rome III diagnostic criteria.~* At least 18 years of age.~* Colonoscopy within the past 10 years to rule out inflammatory bowel disease; or flexible sigmoidoscopy if \< 50 years of age or previous colonoscopy \> 10 years prior.~* Willing to maintain a stable diet. including vitamins, supplements, and nutraceuticals.~Exclusion Criteria:~* Diabetes (Type 1 or 2).~* Lactose intolerance and not controlled by a lactose-free diet.~* Pregnant or planning to become pregnant or is lactating.~* History of HIV or hepatitis B or C.~* Participation in investigational study within past 30 days.~* Taking rifaximin or any other antibiotic within past 60 days.~* Unstable cardiovascular or pulmonary disease, with change in treatment in last 30 days due to worsening disease condition.~* History of GI surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin open-label (Type: EXPERIMENTAL): Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo.
- Double-blind rifaximin (retreatment) (Type: EXPERIMENTAL): Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
- Double-blind placebo (retreatment) (Type: PLACEBO_COMPARATOR): Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).